Ghent University Academic Bibliography

Advanced

Savene® (dexrazoxane) use in clinical practice

Christel Fontaine, Lucien Noens UGent, Pascal Pierre and Jacques de Grève (2012) SUPPORTIVE CARE IN CANCER. 20(5). p.1109-1112
abstract
Introduction Anthracycline extravasation (ACEV) is a rare but potentially devastating event which can result in severe injuries including ulceration and necrosis, slow-healing lesions, serious joint damage and permanent disfigurement. It can delay further scheduled chemotherapy and affect cancer treatment outcome. Savene (R) (dexrazoxane) is the only approved antidote for ACEV in Europe (Totect (R) in the USA) and is administered by intravenous infusion. Its efficacy has been demonstrated in clinical trials with biopsy-verified ACEV with a 98% success rate (no need for surgical debridement) allowing for immediate continuation of chemotherapy in 71% of patients. Adverse events, mainly haematological toxicity, were rapidly reversible. The objective of the study was to assess, in clinical practice, the efficacy and safety profile of Savene (R) for ACEV in different Belgian hospitals. Patients and methods A survey of Savene (R) use was conducted in Belgium from 2007 to 2010 by using a questionnaire sent to 44 hospitals. Main results Data were obtained for 41 cancer patients, 68% (28/41) had ACEV from central venous catheters. Surgical debridement due to ACEV could be avoided in 26 out of 28 extravasations from a central venous access and in 95% (39/41) of the total population treated with Savene (R). Planned chemotherapy was maintained in 73% (30/41) of patients. Eight adverse events were reported in four patients treated with Savene (R), six events were assessed to be of common toxicity criteria grades 1-2 (nausea, leucopenia and arm pain) and two events (neutropenia and pancytopenia) were assessed to be grade 3. Conclusion These data are comparable with the data from previous clinical trials and confirm the efficacy and safety profile of Savene (R) in clinical practice for the treatment of anthracycline extravasation, including extravasations from central venous catheters.
Please use this url to cite or link to this publication:
author
organization
alternative title
Savene (R) (dexrazoxane) use in clinical practice
year
type
journalArticle (original)
publication status
published
subject
keyword
Dexrazoxane, Anthracycline extravasation, Daily practice, Efficacy, Safety, ANTHRACYCLINE EXTRAVASATION, SODIUM-BICARBONATE, MICE
journal title
SUPPORTIVE CARE IN CANCER
Support. Care Cancer
volume
20
issue
5
pages
1109 - 1112
Web of Science type
Article
Web of Science id
000303531700027
JCR category
REHABILITATION
JCR impact factor
2.649 (2012)
JCR rank
6/63 (2012)
JCR quartile
1 (2012)
ISSN
0941-4355
DOI
10.1007/s00520-012-1382-2
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2974426
handle
http://hdl.handle.net/1854/LU-2974426
date created
2012-08-23 14:41:47
date last changed
2012-09-04 11:02:32
@article{2974426,
  abstract     = {Introduction Anthracycline extravasation (ACEV) is a rare but potentially devastating event which can result in severe injuries including ulceration and necrosis, slow-healing lesions, serious joint damage and permanent disfigurement. It can delay further scheduled chemotherapy and affect cancer treatment outcome. Savene (R) (dexrazoxane) is the only approved antidote for ACEV in Europe (Totect (R) in the USA) and is administered by intravenous infusion. Its efficacy has been demonstrated in clinical trials with biopsy-verified ACEV with a 98\% success rate (no need for surgical debridement) allowing for immediate continuation of chemotherapy in 71\% of patients. Adverse events, mainly haematological toxicity, were rapidly reversible. The objective of the study was to assess, in clinical practice, the efficacy and safety profile of Savene (R) for ACEV in different Belgian hospitals. 
Patients and methods A survey of Savene (R) use was conducted in Belgium from 2007 to 2010 by using a questionnaire sent to 44 hospitals. 
Main results Data were obtained for 41 cancer patients, 68\% (28/41) had ACEV from central venous catheters. Surgical debridement due to ACEV could be avoided in 26 out of 28 extravasations from a central venous access and in 95\% (39/41) of the total population treated with Savene (R). Planned chemotherapy was maintained in 73\% (30/41) of patients. Eight adverse events were reported in four patients treated with Savene (R), six events were assessed to be of common toxicity criteria grades 1-2 (nausea, leucopenia and arm pain) and two events (neutropenia and pancytopenia) were assessed to be grade 3. 
Conclusion These data are comparable with the data from previous clinical trials and confirm the efficacy and safety profile of Savene (R) in clinical practice for the treatment of anthracycline extravasation, including extravasations from central venous catheters.},
  author       = {Fontaine, Christel and Noens, Lucien and Pierre, Pascal and de Gr{\`e}ve, Jacques},
  issn         = {0941-4355},
  journal      = {SUPPORTIVE CARE IN CANCER},
  keyword      = {Dexrazoxane,Anthracycline extravasation,Daily practice,Efficacy,Safety,ANTHRACYCLINE EXTRAVASATION,SODIUM-BICARBONATE,MICE},
  language     = {eng},
  number       = {5},
  pages        = {1109--1112},
  title        = {Savene{\textregistered} (dexrazoxane) use in clinical practice},
  url          = {http://dx.doi.org/10.1007/s00520-012-1382-2},
  volume       = {20},
  year         = {2012},
}

Chicago
Fontaine, Christel, Lucien Noens, Pascal Pierre, and Jacques de Grève. 2012. “Savene® (dexrazoxane) Use in Clinical Practice.” Supportive Care in Cancer 20 (5): 1109–1112.
APA
Fontaine, C., Noens, L., Pierre, P., & de Grève, J. (2012). Savene® (dexrazoxane) use in clinical practice. SUPPORTIVE CARE IN CANCER, 20(5), 1109–1112.
Vancouver
1.
Fontaine C, Noens L, Pierre P, de Grève J. Savene® (dexrazoxane) use in clinical practice. SUPPORTIVE CARE IN CANCER. 2012;20(5):1109–12.
MLA
Fontaine, Christel, Lucien Noens, Pascal Pierre, et al. “Savene® (dexrazoxane) Use in Clinical Practice.” SUPPORTIVE CARE IN CANCER 20.5 (2012): 1109–1112. Print.